Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 3/20 | 0.47 |
| ▸ | MMP12 | P39900 | 3/20 | 0.47 |
| ▸ | MMP9 | P14780 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 2/20 | 0.46 |
| ▸ | MMP16 | P51512 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738351 | 0.88 | HSD17B10 (0.64) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL28235915 | 0.86 | HPGD (0.44) | HSD17B10KDM4ECYP2C9CYP2C19HPGD | |
| SCHEMBL15703754 | 0.83 | MEN1 (0.55) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL3749551 | 0.83 | HSD17B10 (0.54) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL3735319 | 0.81 | HSD17B10 (0.59) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL9890648 | 0.81 | HSD17B10 (0.62) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL3736235 | 0.80 | HSD17B10 (0.57) | SMN1; SMN2HSD17B10KDM4ECYP1A2CYP2D6 | |
| SCHEMBL4216332 | 0.79 | MMP2 (0.62) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL3740107 | 0.79 | CYP1A2 (0.51) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 | |
| SCHEMBL3735681 | 0.79 | KDM4E (0.49) | SMN1; SMN2HSD17B10MMP2MMP12MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817031-B1 | CASPASE-10 INHIBITORS FOR PREVENTION AND TREATMENT OF RETINOPATHY | MERCK PATENT GMBH (DE) | 2014-05-21 | — | — | EP | disclosed |
| US-7829721-B2 | Specific caspase-10 inhibitors | MERCK PATENT GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | SMN1; SMN2 3634/4885HSD17B10 120/4885MMP2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.